ReviewChest2022
Lung Transplantation for Patients With COVID-19.
Review in Chest, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 72 citations in OpenAlex.
- The post-COVID-19 pulmonary sequelae: manifestations, mechanisms and treatment strategies.Journal of thoracic disease · 2025Review
- FPCAM: A Weighted Dictionary-Driven Model for Single-Cell Annotation in Pulmonary Fibrosis.Biology · 2025Article
- Lung transplantation for interstitial lung disease.Breathe (Sheffield, England) · 2025Review
- Clinical presentation of severe COVID‑19 with heart failure: A single‑center retrospective study.Experimental and therapeutic medicine · 2024Article
- Associations between the stanford integrated psychosocial assessment for transplant and one-year lung transplant medical and psychosocial outcomes.Journal of behavioral medicine · 2024Article
- Potential for recovery after extremely prolonged VV-ECMO support in well-selected severe COVID-19 patients: a retrospective cohort study.BMC pulmonary medicine · 2024Article
- Experience of a novel lung transplant program in Mexico.Frontiers in transplantation · 2024Article
- Coronavirus disease 2019 in a patient with pulmonary fibrosis and emphysema: An autopsy report.Heliyon · 2023Article
- Single-Center Experience With Lung Transplant Evaluation Referrals of Acute Respiratory Distress Syndrome Patients During the COVID-19 Pandemic: How Do You Make Up For Lost Time?Critical care explorations · 2023Article
- Pulmonary Sequelae of Coronavirus Disease 2019.Physical medicine and rehabilitation clinics of North America · 2023Review
- Infectious Complications of Lung Transplant for Coronavirus Disease 2019-Associated Lung Injury: A Single-Center Case-Control Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Timing of Lung Transplant Referral in Patients with Severe COVID-19 Lung Injury Supported by ECMO.Journal of clinical medicine · 2023Article
- Oximetry at admission as a predictor of tomographic and functional impairment after 3-6 months in hospitalized patients with COVID-19.The Journal of international medical research · 2023Observational
- Lung Transplantation in Coronavirus-19 Patients: What We Have Learned So Far.Clinics in chest medicine · 2023Review
- Medicine Faculty Students' Perspective on Cadaver and Organ Donation in the COVID-19 Pandemic.Transplantation proceedings · 2023Article
- Lung Transplantation for Coronavirus Disease-2019 Patients and Coronavirus Disease-2019 in Lung Transplant Recipients.Clinics in chest medicine · 2023Review
- Lessons learned by thoracic surgeons during the COVID-19 pandemic.Journal of thoracic disease · 2023Article
- Early Outcomes of COVID-19 Lung Transplantation Recipients in Korea: A Single-Center Study.Journal of chest surgery · 2023Article
- Serum hyaluronic acid and procollagen III, N-terminal propeptide levels are highly associated with disease severity and predict the progression of COVID-19.Frontiers in cellular and infection microbiology · 2023Article
- LCCNN: a Lightweight Customized CNN-Based Distance Education App for COVID-19 Recognition.Mobile networks and applications : MONET · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has caused acute lung injury in millions of individuals worldwide. Some patients develop COVID-related acute respiratory distress syndrome (CARDS) and cannot be liberated from mechanical ventilation. Others may develop post-COVID fibrosis, resulting in substantial disability and need for long-term supplemental oxygen. In both of these situations, treatment teams often inquire about the possibility of lung transplantation. In fact, lung transplantation has been successfully employed for both CARDS and post-COVID fibrosis in a limited number of patients worldwide. Lung transplantation after COVID infection presents a number of unique challenges that transplant programs must consider. In those with severe CARDS, the inability to conduct proper psychosocial evaluation and pretransplantation education, marked deconditioning from critical illness, and infectious concerns regarding viral reactivation are major hurdles. In those with post-COVID fibrosis, our limited knowledge about the natural history of recovery after COVID-19 infection is problematic. Increased knowledge of the likelihood and degree of recovery after COVID-19 acute lung injury is essential for appropriate decision-making with regard to transplantation. Transplant physicians must weigh the risks and benefits of lung transplantation differently in a post-COVID fibrosis patient who is likely to remain stable or gradually improve in comparison with a patient with a known progressive fibrosing interstitial lung disease (fILD). Clearly lung transplantation can be a life-saving therapeutic option for some patients with severe lung injury from COVID-19 infection. In this review, we discuss how lung transplant providers from a number of experienced centers approach lung transplantation for CARDS or post-COVID fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.